Hemab Therapeutics Announces Positive Complete Phase 2 Data for Sutacimig in Glanzmann Thrombasthenia at ASH 2025; Plans to Advance to Pivotal Phase 3 Study

Phase 2 Clinical Data Highlights: Hemab's Phase 2 study of sutacimig (N=34) is intended to address a profound gap in care for GT as there are currently no effective prophylactic treatment options.
Seeking Alpha

Hemab Therapeutics Presents Positive Clinical and Preclinical Data Across Bleeding Disorder Pipeline at ISTH 2025 Congress

Sutacimig Phase 2 interim results demonstrate >50% reduction in treated bleeding event and prophylactic treatment potential in Glanzmann thrombasthenia HMB-002 clinical proof-of-mechanism data in Von ...
FiercePharma

FDA Approves Biogen Idec's Eloctate™, First Hemophilia A Therapy to Extend the Interval Between Prophylactic Infusions, for Both Adults and Children

FDA APPROVES BIOGEN IDEC'S ELOCTATE™, FIRST HEMOPHILIA A THERAPY TO EXTEND THE INTERVAL BETWEEN PROPHYLACTIC INFUSIONS, FOR BOTH ADULTS AND CHILDREN – Only Hemophilia A Therapy to Provide Bleeding ...
Nature

Secondary prophylaxis for variceal bleeding

Variceal rebleeding frequently develops in patients with cirrhosis after an initial episode of acute variceal hemorrhage. The best prophylactic treatment for variceal rebleeding has not been clearly ...
Fierce Pharma

ASH: Pfizer, aiming to level the hemophilia playing field, trots out new Hympavzi data

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...
Healio

Concizumab prophylaxis reduces bleeding rates for patients with hemophilia

Please provide your email address to receive an email when new articles are posted on . Concizumab prophylaxis led to lower annualized bleeding rates than no prophylaxis. Treatment with concizumab ...
Healio

Fitusiran prophylaxis ‘great option’ for reducing bleeds in people with hemophilia A or B

Please provide your email address to receive an email when new articles are posted on . The subcutaneously administered small interfering RNA therapy conferred a 90.8% reduction in the annualized ...
Monthly Prescribing Reference

Wilate Approved for Routine Prophylaxis in Von Willebrand Disease

Findings showed that routine prophylaxis with wilate resulted in an 84% reduction in mean total ABRs compared with on-demand treatment. The Food and Drug Administration (FDA) has expanded the approval ...
The American Journal of Managed Care

Targeted Therapies, Key Subgroup Insights to Watch at ASH 2025

The upcoming American Society of Hematology (ASH) 2025 meeting is poised to spotlight several pivotal developments across ...
Nasdaq

Novo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors

Bagsværd, Denmark, 18 October 2024 – Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, ...
The American Journal of Managed Care

Bleeding, Damage Common in Pediatric Hemophilia Despite Prophylaxis

About a quarter of joints examined had at least 1 joint bleed. Although prophylaxis is the gold standard of treatment for children with hemophilia, a new report highlights the need to vigilantly ...
Nature

Therapy Insight: prophylaxis of stress-induced gastrointestinal bleeding in critically ill patients

Stress-induced gastrointestinal bleeding is associated with increased morbidity and mortality in critically ill patients. Within the past few decades, the incidence of stress-induced gastrointestinal ...